
Sign up to save your podcasts
Or


This week on Diagnosing Dx, I’m joined by Janine McMurdie, Chief Commercial Officer at Pictor, a company unlocking the next wave of innovation in diagnostics through proteomics.
With a career spanning industry giants like Amgen and IonTorrent, Janine shares what it takes to lead in a fast-evolving space - where scalability, speed, and strategy matter more than ever.
We dive into how Pictor’s flexible platform is pushing proteomics toward its tipping point, why patient-centric design is critical, and how regulatory momentum is working in their favour.
Â
🔥 What You’ll Learn:
• Why proteomics is the "new genomics" in diagnostics
• How Pictor is building a fast, scalable, and cost-effective platform
• The impact of recent regulatory changes on startup strategy
• How strong leadership and patient focus shape product success
Â
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of Diagnostics.
This week on Diagnosing Dx, I’m joined by Dr. Sam Agus, a neurologist and diagnostics innovator with over 20 years of experience in clinical trials, biomarker development, and early-stage ventures.
Â
In this candid conversation, Sam shares the hard truths about why diagnostics companies struggle for funding, why prognostics are quietly becoming the next frontier, and how early partnerships - especially with pharma, can make or break a startup.
With deep insights from his work in chronic kidney disease, Alzheimer’s, and early diagnostics ventures, this episode is essential listening for anyone building, backing, or navigating the Dx space.
Â
🔥 What You’ll Learn:
Â
• Why prognostic biomarkers are shaping the future of diagnostics
• How early-stage partnerships with pharma drive commercial success
• The biggest funding challenges facing Dx startups today
• What investors really want in a diagnostics pitch
Whether you're a founder, investor, or clinical innovator, Sam’s experience offers practical insight into the future of diagnostics, and what it takes to get there.
Â
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of Diagnostics.
This week on Diagnosing Dx, we’re joined by Kim Langone, SVP of R&D at Fellow Health, and former 10th employee at Genomic Health, where for 19 years, she played a pivotal role in developing Oncotype DX, a landmark diagnostic test for breast cancer.
Â
With 24 years of experience in molecular diagnostics, Kimshares what it takes to build breakthrough science in a startup, scale it, and navigate the evolving challenges of today’s diagnostics landscape.
Â
🔥 In This Episode, You’ll Learn:
 • How early-stage culture and leadership shape long-term innovation
• What it’s like to build diagnostics from scratch—then scale with impact
• Why commercialization and reimbursement strategy are non-negotiable
• What scientists and R&D leaders need to consider when joining startups vs. corporates
Whether you're scaling science, leading R&D, or enteringthe diagnostics field, Kim offers hard-earned insights for building a lasting career—and technology that truly matters.
Â
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of Diagnostics.
This week on Diagnosing Dx, we’re joined by Heinz Steneberg, President and CEO of MDSS, for a deep dive into the role of Regulatory Strategy in Diagnostics and MedTech startups.
From early-stage planning to FDA engagement, we cover the decisions that make or break go-to-market timelines - and how emerging models are shaping the regulatory future.
🔥 What You’ll Learn:
• How to use FDA pre-submissions to clarify your path to approval
• What it takes to secure Breakthrough Designation - and why it matters
• The most common regulatory missteps made by startups
• How AI and direct-to-consumer models are shifting regulatory expectations
• What support MDSS provides to help startups navigate compliance
Whether you're a founder, operator, or innovator in diagnostics, this episode delivers clear, practical insights to help you build smarter - and faster.
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of Diagnostics.
From the publisher's feed